Impact of macrolide therapy in patients hospitalized with pseudomonas aeruginosa community-acquired pneumonia

Chest

Volumn 145, Issue 5, 2014, Pages 1114-1120

  Laserna, Elena ^a,b   Sibila, Oriol ^b,c,d   Fernandez, Juan Felipe ^b,e   Maselli, Diego Jose ^b,e   Mortensen, Eric M ^f,g   Anzueto, Antonio ^b,e   Waterer, Grant ^h,i   Restrepo, Marcos I ^b,e  

^a Hospital Comarcal de Mollet   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^f North Texas Veterans Health Care System   (United States)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GENTAMICIN; HYPERTENSIVE AGENT; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CAUCASIAN; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

AGED; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HOSPITALS, VETERANS; HUMANS; INPATIENTS; LENGTH OF STAY; MACROLIDES; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84899803824     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1607     Document Type: Article

References (34)

1. Mandell LA , Wunderink RG , Anzueto A , et al ; Infectious Diseases Society of America ; American Thoracic Society . Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults . Clin Infect Dis . 2007; 44(suppl 2): S27-S72.
2. Woodhead M , Blasi F , Ewig S , et al ; European Respiratory Society ; European Society of Clinical Microbiology and Infectious Diseases . Guidelines for the management of adult lower respiratory tract infections [published correction appears in Eur Respir J . 2006;27(2):439] .
3. Eur Respir J . 2005 ; 26 (6): 1138-1180.
4. Kanoh S , Rubin BK . Mechanisms of action and clinical application of macrolides as immunomodulatory medications . Clin Microbiol Rev . 2010 ; 23 (3): 590-615.
5. Giamarellos-Bourboulis EJ . Macrolides beyond the conventional antimicrobials: a class of potent immunomodulatorS . Int J Antimicrob Agents . 2008 ; 31 (1): 12-20.
6. Amsden GW . Anti-infl ammatory effects of macrolides-an underappreciated benefi t in the treatment of communityacquired respiratory tract infections and chronic infl ammatory pulmonary conditions? J Antimicrob Chemother . 2005 ; 55 (1): 10-21.
7. Waterer GW , Somes GW , Wunderink RG . Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia . Arch Intern Med . 2001 ; 161 (15): 1837-1842.
8. Martinez JA , Horcajada JP , Almela M , et al . Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia . Clin Infect DiS . 2003 ; 36 (4): 389-395.
9. Baddour LM, Yu VL, Klugman KP , et al; International Pneumococcal Study Group . Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia . Am J Respir Crit Care Med . 2004 ; 170 (4): 440-444.
10. Metersky ML , Ma A , Houck PM , Bratzler DW . Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fl uoroquinolones . Chest . 2007 ; 131 (2): 466-473.
11. Rodriguez A , Mendia A , Sirvent JM , et al ; CAPUCI Study Group . Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock . Crit Care Med . 2007 ; 35 (6): 1493-1498.
12. Restrepo MI , Mortensen EM , Waterer GW , Wunderink RG , Coalson JJ , Anzueto A . Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia . Eur Respir J . 2009 ; 33 (1): 153-159.
13. Fujitani S , Sun HY , Yu VL , Weingarten JA . Pneumonia due to Pseudomonas aeruginosa : part I: epidemiology, clinical diagnosis, and source . Chest . 2011 ; 139 (4): 909-919.
14. Arancibia F , Bauer TT , Ewig S , et al . Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa : incidence, risk, and prognosis . Arch Intern Med . 2002 ; 162 (16): 1849-1858.
15. von Baum H, Welte T , Marre R, Suttorp N, Ewig S; CAPNETZ study group . Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa : diagnosis, incidence and predictors . Eur Respir J . 2010 ; 35 (3): 598-605.
16. Altenburg J , de Graaff CS , Stienstra Y , et al . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fi brosis bronchiectasis: the BAT randomized controlled trial . JAMA . 2013 ; 309 (12): 1251-1259.
17. Saiman L, Marshall BC, Mayer-Hamblett N, et al; Macrolide Study Group . Azithromycin in patients with cystic fi brosis chronically infected with Pseudomonas aeruginosa : a randomized controlled trial . JAMA . 2003 ; 290 (13): 1749-1756.
18. Albert RK , Connett J , Bailey WC , et al ; COPD Clinical Research Network . Azithromycin for prevention of exacerbations of COPD . N Engl J Med . 2011 ; 365 (8): 689-698.
19. Kudoh S, Azuma A, Yamamoto M, Izumi T , Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin . Am J Respir Crit Care Med . 1998 ; 157 (6): 1829-1832.
20. Charlson M , Szatrowski TP , Peterson J , Gold J . Validation of a combined comorbidity index . J Clin Epidemiol . 1994; 47(11): 1245-1251.
21. Mortensen EM , Coley CM , Singer DE , et al . Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study . Arch Intern Med . 2002 ; 162 (9): 1059-1064.
22. Sohn MW , Arnold N , Maynard C , Hynes DM . Accuracy and completeness of mortality data in the Department of Veterans Affairs . Popul Health Metr . 2006 ; 4 : 2.
23. Aspa J , Rajas O , Rodriguez de Castro F , et al ; Pneumococcal Pneumonia in Spain Study Group . Impact of initial antibiotic choice on mortality from pneumococcal pneumonia . Eur Respir J . 2006 ; 27 (5): 1010-1019.
24. Dwyer R , Ortqvist A , Aufwerber E , et al . Addition of a macrolide to a b -lactam in bacteremic pneumococcal pneumonia . Eur J Clin Microbiol Infect Dis . 2006 ; 25 (8): 518-521.
25. Paul M , Nielsen AD , Gafter-Gvili A , et al . The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis . Eur Respir J . 2007 ; 30 (3): 525-531.
26. Asadi L , Sligl WI , Eurich DT , et al . Macrolide-based regimens and mortality in hospitalized patients with communityacquired pneumonia: a systematic review and meta-analysiS . Clin Infect Dis . 2012 ; 55 (3): 371-380.
27. Waterer GW , Rello J , Wunderink RG . Management of community-acquired pneumonia in adults . Am J Respir Crit Care Med . 2011 ; 183 (2): 157-164.
28. Ma L , Conover M , Lu H , Parsek MR , Bayles K , Wozniak DJ . Assembly and development of the Pseudomonas aeruginosa biofi lm matrix . PLoS Pathog . 2009 ; 5 (3): e1000354.
29. Giamarellos-Bourboulis EJ , Adamis T , Laoutaris G , et al . Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa . Antimicrob Agents Chemother . 2004 ; 48 (1): 93-99.
30. Kang CI, Song JH, Oh WS, Ko KS, Chung DR, Peck KR; Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group . Clinical outcomes and risk factors of communityacquired pneumonia caused by gram-negative bacilli . Eur J Clin Microbiol Infect Dis . 2008 ; 27 (8): 657-661.
31. Falguera M , Carratala J , Ruiz-Gonzalez A , et al . Risk factors and outcome of community-acquired pneumonia due to gramnegative bacilli . Respirology . 2009 ; 14 (1): 105-111.
32. Aronsky D , Haug PJ , Lagor C , Dean NC . Accuracy of administrative data for identifying patients with pneumonia . Am J Med Qual . 2005 ; 20 (6): 319-328.
33. Ewig S , Welte T , Chastre J , Torres A . Rethinking the concepts of community-acquired and health-care-associated pneumonia . Lancet Infect Dis . 2010 ; 10 (4): 279-287.
34. Attridge RT , Frei CR , Restrepo MI , et al . Guidelineconcordant therapy and outcomes in healthcare-associated pneumonia . Eur Respir J . 2011 ; 38 (4): 878-887.